Peptides DB
Research-centric peptide and protocol reference hub

BPC-157 vs Dihexa

Updated November 4, 2026 · Reviewed by the PeptidesDB Editorial team

BPC-157: Research use — not FDA-approvedDihexa: Research use — not FDA-approved

A data-driven comparison of BPC-157 and Dihexa (also searched as Dihexa vs BPC-157) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.

Verdict

BPC-157 centers on healing, while Dihexa leans toward neuro. On indexed research, BPC-157 is ahead (BPC-157: 16 studies, Human evidence; Dihexa: 11, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.

Key takeaways

  • •BPC-157 is strongest for healing; Dihexa for neuro.
  • •Evidence: BPC-157 Human evidence (16 studies) vs Dihexa Human clinical (11).
  • •Both are research-use compounds — not FDA-approved.

Effect profiles, overlaid

BPC-157Dihexa

At a glance

BPC-157Human evidence

Angiogenesis | Soft-tissue repair

Strongest: HealingStudies: 16Level: Preclinical
DihexaHuman clinical

Neuroprotection | Cognitive enhancement

Strongest: NeuroStudies: 11Level: Moderate Research

BPC-157 vs Dihexa: side-by-side

MetricBPC-157Dihexa
ClassHealingNeuro
Regulatory statusResearch use onlyResearch use only
Evidence gradeHuman evidenceHuman clinical
Studies indexed1611
Research levelPreclinicalModerate Research
Strongest effectHealing & recoveryNeuro & mood
Healing & recovery4.0▲3.0
Muscle & body comp3.0▲1.0
Metabolic & appetite2.0▲1.0
Neuro & mood2.05.0▲
Sleep & circadian1.0▲1.0▲
Inflammation & immune4.0▲2.0
Skin & aesthetics1.0▲0.0

▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).

Mechanism & pharmacokinetics

PropertyBPC-157Dihexa
MechanismBody-protective compound (pentadecapeptide); cytoprotective, pro-angiogenic signalingPI3K/AKT signaling pathway activation
RouteSubcutaneous / oral (research use)—

Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.

What is BPC-157?

BPC-157, or Body Protective Compound-157, is a synthetic peptide derived from a protein found in human gastric juice. It has attracted attention for its potential roles in soft-tissue repair, gastrointestinal (GI) support, and the modulation of inflammation. The peptide is believed to exert its effects through several mechanisms, including the promotion of angiogenesis, modulation of growth factors, and reduction of oxidative stress and inflammation.

Full BPC-157 profile, mechanism & studies →

What is Dihexa?

Experimental nootropic peptide investigated for neuroprotection, memory, and stroke/spinal-cord recovery.

Full Dihexa profile, mechanism & studies →

Which is better for your goal?

GoalBetter fitWhy
HealingBPC-1574.0/5 effect signal
MuscleBPC-1573.0/5 effect signal
MetabolicBPC-1572.0/5 effect signal
NeuroDihexa5.0/5 effect signal
SleepEvenBoth ~1.0/5
InflammationBPC-1574.0/5 effect signal
SkinBPC-1571.0/5 effect signal

Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.

Can you stack BPC-157 and Dihexa?

People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.

BPC-157 vs Dihexa: side effects

BPC-157

No community-reported effects logged yet.

Dihexa

No community-reported effects logged yet.

Anonymous community reports (count = number of reports), not clinical incidence rates.

What the research says

BPC-157 has 16 approved studies indexed (Human evidence), and Dihexa has 11 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.

Frequently asked questions

Is BPC-157 or Dihexa better?

It depends on your goal. BPC-157 is strongest for healing; Dihexa for neuro. BPC-157 has more indexed studies (16). See the goal-by-goal breakdown above.

Is BPC-157 or Dihexa better for weight loss?

BPC-157 shows the stronger metabolic & appetite profile (2.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.

Is BPC-157 or Dihexa better for muscle?

BPC-157 leads on the muscle & body-composition axis (3.0/5).

Which has more research, BPC-157 or Dihexa?

BPC-157 has 16 approved studies indexed (Human evidence); Dihexa has 11 (Human clinical). Higher counts mean more to read, not proven superiority.

Can you stack BPC-157 and Dihexa?

Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.

What are the side effects of BPC-157 vs Dihexa?

BPC-157: no community-reported effects logged yet. Dihexa: none logged yet. These are anonymous reports, not incidence rates — see each profile.

Is BPC-157 or Dihexa FDA-approved?

BPC-157 is a research-use compound and is not FDA-approved. Dihexa is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.

Is Dihexa better than BPC-157?

For neuro, Dihexa has the edge; for healing, BPC-157 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.

Comparing related peptides

Regulatory & legal status

BPC-157 and Dihexa are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed November 4, 2026.